Note 8 - Noncontrolling Interest - Clyra Medical (Details Textual)
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
12 Months Ended |
72 Months Ended |
|
Dec. 04, 2024
USD ($)
|
Oct. 31, 2025
USD ($)
$ / shares
shares
|
Oct. 31, 2023
USD ($)
$ / shares
shares
|
Jun. 30, 2026
USD ($)
$ / shares
shares
|
Mar. 31, 2026
USD ($)
$ / shares
shares
|
Jun. 30, 2025
USD ($)
$ / shares
shares
|
Mar. 31, 2025
USD ($)
|
Jun. 30, 2026
USD ($)
$ / shares
shares
|
Jun. 30, 2025
USD ($)
$ / shares
shares
|
Dec. 31, 2025
USD ($)
shares
|
Dec. 31, 2024
USD ($)
|
Jun. 30, 2026
USD ($)
$ / shares
shares
|
| Warrants and Rights Outstanding |
[1] |
|
|
|
$ 0
|
|
|
|
$ 0
|
|
|
|
$ 0
|
| Class of Warrant or Right, Issued During Period (in shares) | shares |
|
|
|
|
|
|
|
|
1,198,832
|
|
|
|
|
| Stock Issued During Period, Value, Issued for Services |
|
|
|
|
$ 236,000
|
$ 46,000
|
$ 212,000
|
$ 61,000
|
|
|
|
|
|
| Share Price (in dollars per share) | $ / shares |
|
|
|
|
$ 0.11
|
|
|
|
$ 0.11
|
|
|
|
$ 0.11
|
| Clyra Medical [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Investment Owned, Balance, Shares (in shares) | shares |
|
|
|
|
5,305,156
|
|
|
|
5,305,156
|
|
5,305,156
|
|
5,305,156
|
| Clyra Medical [Member] | Preferred Stock, Series A [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Investment Owned, Balance, Shares (in shares) | shares |
|
|
|
|
165,765
|
|
|
|
165,765
|
|
165,765
|
|
165,765
|
| Measurement Input, Price Volatility [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants and Rights Outstanding, Measurement Input |
|
|
|
|
|
|
|
|
|
|
0
|
|
|
| Maximum [Member] | Measurement Input, Price Volatility [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants and Rights Outstanding, Measurement Input |
|
|
|
|
0.66
|
|
|
|
0.66
|
|
|
|
0.66
|
| Minimum [Member] | Measurement Input, Price Volatility [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants and Rights Outstanding, Measurement Input |
|
|
|
|
0.62
|
|
|
|
0.62
|
|
|
|
0.62
|
| Clyra Medical [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares, Outstanding (in shares) | shares |
|
|
|
|
11,378,545
|
|
|
|
11,378,545
|
|
11,378,545
|
|
11,378,545
|
| Shares, Issued (in shares) | shares |
|
|
|
|
11,378,545
|
|
|
|
11,378,545
|
|
11,378,545
|
|
11,378,545
|
| Finance Lease, Liability |
|
|
|
|
$ 311,000
|
|
|
|
$ 311,000
|
|
|
|
$ 311,000
|
| Clyra Medical [Member] | Sale Leaseback of Equipment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from Sale of Property, Plant, and Equipment |
|
$ 350,000
|
|
|
|
|
|
|
|
|
|
|
|
| Financing Receivable, after Allowance for Credit Loss |
|
$ 82,000
|
|
|
|
|
|
|
|
|
|
|
|
| Receivable with Imputed Interest, Effective Yield (Interest Rate) |
|
15.00%
|
|
|
|
|
|
|
|
|
|
|
|
| Lessee, Finance Lease, Purchase Option, Amount |
|
$ 82,000
|
|
|
|
|
|
|
|
|
|
|
|
| Lessee, Finance Lease, Term of Contract (Year) |
|
49 years
|
|
|
|
|
|
|
|
|
|
|
|
| Finance Lease, Liability |
|
|
|
|
$ 375,000
|
|
|
|
375,000
|
|
|
|
375,000
|
| Clyra Medical [Member] | Vendors [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, Issued for Services (in shares) | shares |
|
|
|
|
2,685
|
0
|
|
|
|
9,698
|
|
|
|
| Stock Issued During Period, Value, Issued for Services |
|
|
|
|
$ 17,000
|
|
|
|
|
$ 60,000
|
|
|
|
| Clyra Medical [Member] | Employees and Consultants [Member] | Share-Based Payment Arrangement, Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value |
|
|
|
|
|
|
|
|
449,000
|
$ 92,000
|
|
|
|
| Share Price (in dollars per share) | $ / shares |
|
|
|
|
|
$ 4.5
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate |
|
|
|
|
|
30.00%
|
|
|
|
|
|
|
|
| Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount |
|
|
|
|
$ 1,278,000
|
|
|
|
$ 1,278,000
|
|
|
|
$ 1,278,000
|
| Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) |
|
|
|
|
|
|
|
|
2 years
|
|
|
|
|
| Clyra Medical [Member] | Series A Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares, Outstanding (in shares) | shares |
|
|
|
|
746,418
|
|
|
|
746,418
|
|
746,418
|
|
746,418
|
| Shares Issued, Price Per Share (in dollars per share) | $ / shares |
|
|
|
$ 3.1
|
|
|
|
|
|
|
|
|
|
| Preferred Stock, Dividend Rate, Percentage |
|
|
|
15.00%
|
|
|
|
|
|
|
|
|
|
| Preferred Stock, Convertible, Sale of Stock Amount |
|
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
|
|
| Preferred Stock Dividends and Other Adjustments |
|
|
|
|
|
|
|
|
$ 1,109,000
|
|
$ 937,000
|
|
|
| Clyra Medical [Member] | Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares, Outstanding (in shares) | shares |
|
|
|
|
330,000
|
|
|
|
330,000
|
|
330,000
|
|
330,000
|
| Clyra Medical [Member] | Preferred Class A [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, New Issues (in shares) | shares |
|
|
|
746,418
|
|
|
|
|
|
|
|
|
|
| Proceeds from Issuance of Preferred Stock and Preference Stock |
|
|
|
$ 1,800,000
|
|
|
|
|
|
|
|
|
|
| Clyra Medical [Member] | Revolving Credit Facility [Member] | Vernal Bay Capital Group, LLC [Member] | Inventory Line of Credit [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Line of Credit Facility, Maximum Borrowing Capacity |
|
|
|
|
$ 1,000,000
|
|
|
|
$ 1,000,000
|
|
|
|
$ 1,000,000
|
| Proceeds from Lines of Credit, Total |
|
|
|
|
|
|
|
|
|
|
|
|
$ 260,000
|
| Long-Term Line of Credit |
|
|
|
|
|
|
|
|
|
|
$ 134,000
|
|
|
| Clyra Medical [Member] | Warrants Issued Concurrently with Note Payable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
|
|
15.00%
|
|
|
15.00%
|
|
|
|
| Debt Instrument, Face Amount |
|
|
|
|
|
|
$ 575,000
|
|
|
$ 575,000
|
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares |
|
|
|
|
$ 6
|
|
|
|
$ 6
|
|
|
|
$ 6
|
| Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares |
|
|
|
|
72,667
|
|
|
|
72,667
|
|
|
|
72,667
|
| Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares |
|
|
|
|
|
|
$ 6.5
|
|
|
$ 6.5
|
|
|
|
| Clyra Medical [Member] | Warrant In Connection With Convertible Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares |
|
|
|
|
226,344
|
|
|
|
226,344
|
|
|
|
226,344
|
| Warrants and Rights Outstanding |
|
|
|
|
$ 353,000
|
|
|
|
$ 353,000
|
|
|
|
$ 353,000
|
| Warrants and Rights Outstanding, Measurement Input |
|
|
|
|
6
|
|
|
|
6
|
|
|
|
6
|
| Clyra Medical [Member] | Warrant In Connection With Convertible Note [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares |
|
|
|
|
$ 7.5
|
|
|
|
$ 7.5
|
|
|
|
$ 7.5
|
| Clyra Medical [Member] | Warrant in Connection with Guaranteed Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares |
|
|
|
|
|
|
88,462
|
|
|
88,462
|
|
|
|
| Warrants and Rights Outstanding |
|
|
|
|
|
|
$ 80,000
|
|
|
$ 80,000
|
|
|
|
| Long-Term Debt, Gross |
|
|
|
|
$ 3,970,000
|
|
|
|
$ 3,970,000
|
|
575,000
|
|
$ 3,970,000
|
| Clyra Medical [Member] | Warrants Issued With Secured Promissory Notes and Convertible Promissory Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Discount Percentage |
|
|
|
|
30.00%
|
|
|
|
30.00%
|
|
|
|
30.00%
|
| Clyra Medical [Member] | Warrants Issued in Conjunction With the Sale of Series A Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants and Rights Outstanding |
|
|
|
$ 524,000
|
|
|
|
|
|
|
|
|
|
| Warrants and Rights Outstanding, Term (Month) |
|
|
|
3 years
|
|
|
|
|
|
|
|
|
|
| Shares Issued, Price Per Share (in dollars per share) | $ / shares |
|
|
|
$ 3.72
|
|
|
|
|
|
|
|
|
|
| Clyra Medical [Member] | Vendor Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares |
|
|
|
|
|
|
$ 6
|
|
|
$ 6
|
|
|
|
| Warrants and Rights Outstanding |
|
|
|
|
|
|
$ 6,000
|
|
|
$ 6,000
|
|
|
|
| Warrants and Rights Outstanding, Term (Month) |
|
|
|
|
|
|
5 years
|
|
|
5 years
|
|
|
|
| Class of Warrant or Right, Issued During Period (in shares) | shares |
|
|
|
|
|
|
|
|
|
7,849
|
|
|
|
| Clyra Medical [Member] | Notes Payable, Other Payables [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from Issuance of Debt |
|
|
|
|
|
|
|
|
|
|
|
$ 1,064,000
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
15.00%
|
|
|
|
15.00%
|
|
|
15.00%
|
15.00%
|
| Debt Instrument, Face Amount |
|
|
|
|
$ 3,395,000
|
|
|
|
$ 3,395,000
|
|
$ 436,000
|
|
$ 3,395,000
|
| Warrants and Rights Outstanding |
|
|
|
|
99,000
|
|
|
|
99,000
|
|
|
|
99,000
|
| Long-Term Debt, Gross |
|
|
|
|
1,500,000
|
|
|
|
1,500,000
|
|
|
|
1,500,000
|
| Clyra Medical [Member] | Notes Payable, Other Payables [Member] | Biolargo [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payments to Acquire Notes Receivable |
|
|
|
|
|
|
|
|
|
|
|
$ 200,000
|
|
| Long-Term Debt, Gross |
|
|
|
|
$ 200,000
|
|
|
|
$ 200,000
|
|
|
|
$ 200,000
|
| Clyra Medical [Member] | Convertible Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Instrument, Interest Rate, Stated Percentage |
|
|
|
|
15.00%
|
|
|
|
15.00%
|
|
|
|
15.00%
|
| Clyra Medical Technologies [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, New Issues (in shares) | shares |
|
|
|
|
|
|
|
|
0
|
49,167
|
|
|
|
| Proceeds from Issuance or Sale of Equity |
|
|
|
|
|
|
|
|
|
$ 295,000
|
|
|
|
| Clyra Medical Technologies [Member] | Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Issued During Period, Shares, New Issues (in shares) | shares |
|
|
330,000
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from Issuance of Preferred Stock and Preference Stock |
|
|
$ 2,145,000
|
|
|
|
|
|
|
|
|
|
|
| Clyra Medical Technologies [Member] | Warrants Issued With Secured Promissory Notes and Convertible Promissory Notes [Member] | Maximum [Member] | Valuation Technique, Black-Scholes-Merton Model [Member] | Measurement Input, Price Volatility [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants and Rights Outstanding, Measurement Input |
|
|
|
|
52
|
|
|
|
52
|
|
|
|
52
|
| Clyra Medical Technologies [Member] | Warrants Issued With Secured Promissory Notes and Convertible Promissory Notes [Member] | Minimum [Member] | Valuation Technique, Black-Scholes-Merton Model [Member] | Measurement Input, Price Volatility [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants and Rights Outstanding, Measurement Input |
|
|
|
|
35
|
|
|
|
35
|
|
|
|
35
|
| Clyra Medical Technologies [Member] | Warrants Issued in October 2025 Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares |
|
|
$ 7.5
|
|
|
|
|
|
|
|
|
|
|
| Warrants and Rights Outstanding |
|
|
$ 94,000
|
|
|
|
|
|
|
|
|
|
|
| Warrants and Rights Outstanding, Term (Month) |
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares |
|
|
165,000
|
|
|
|
|
|
|
|
|
|
|
| Clyra Medical Technologies [Member] | March 31, 2025 Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares |
|
|
|
|
|
|
$ 7.5
|
|
|
$ 7.5
|
|
|
|
| Warrants and Rights Outstanding |
|
|
|
|
|
|
$ 38,000
|
|
|
$ 38,000
|
|
|
|
| Class of Warrant or Right, Issued During Period (in shares) | shares |
|
|
|
|
|
|
|
|
|
24,584
|
|
|
|
| Number of Accredited Investors |
|
|
|
|
|
|
5
|
|
|
5
|
|
|
|
|
|